A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis

Project: Research

AcronymQUASAR
StatusActive
Effective start/end date24/10/1923/10/24

Keywords

  • clinical trial
  • phase 2 and 3 study
  • colitis
  • treatment efficacy